Dyskinesia, Drug-Induced (diagnosis) < Dyskinesia, Drug-Induced (drug therapy) < Dyskinesia, Drug-Induced (enzymology)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 75.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000062 (1999)	S. Spieker [Allemagne] ; P A Löschmann ; T. Klockgether	The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
000105 (1999)	J M Brotchie [Royaume-Uni] ; S H Fox	Quantitative assessment of dyskinesias in subhuman primates.
000106 (1999)	C G Goetz [États-Unis]	Rating scales for dyskinesias in Parkinson's disease.
000145 (1999)	P. Ka Ovsk [République tchèque] ; H. Streitová ; M. Bares ; H. Hortová	Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect.
000190 (2000)	C. Ramaker [Pays-Bas] ; W J Van De Beek ; M J Finken ; B J Van Hilten	The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: a systematic review.
000238 (2000)	A J Manson [Royaume-Uni] ; E. Iakovidou ; A J Lees	Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
000245 (2000)	A. Rapaport [Israël] ; M. Sadeh ; D. Stein ; J. Levine ; P. Sirota ; T. Mosheva ; S. Stir ; A. Elitzur ; I. Reznik ; D. Geva ; J M Rabey	Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia.
000314 (2000)	E. Růzicka [République tchèque] ; J. Roth ; R. Jech ; P. Busek	Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
000327 (2000)	Werner Poewe [Autriche] ; G K Wenning	Apomorphine: an underutilized therapy for Parkinson's disease.
000329 (2000)	S A Treseder [Royaume-Uni] ; L A Smith ; P. Jenner	Endogenous dopaminergic tone and dopamine agonist action.
000339 (2000)	E. Luginger [Autriche] ; G K Wenning ; S. Bösch ; Werner Poewe [Autriche]	Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
000512 (2001)	P. Del Dotto [Italie] ; N. Pavese ; G. Gambaccini ; S. Bernardini ; L V Metman ; T N Chase ; U. Bonuccelli	Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
000548 (2001)	O. Rascol [France] ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A M Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J L Montastruc ; Yves Agid [France]	Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
000674 (2002)	Petr Kanovsk [République tchèque] ; Dagmar Kubová ; Martin Bares ; Hana Hortová ; Hana Streitová ; Ivan Rektor ; Vladimír Znojil	Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
000817 (2002)	Daniel Tarsy [États-Unis] ; Gerald Indorf	Tardive tremor due to metoclopramide.
000934 (2002)	Alice J. Manson [Royaume-Uni] ; Kirsten Turner ; Andrew J. Lees	Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
000B15 (2003)	Juha-Matti Savola [Finlande] ; Michael Hill ; Mia Engstrom ; Hannele Merivuori ; Siegfried Wurster ; Steven G. Mcguire ; Susan H. Fox ; Alan R. Crossman ; Jonathan M. Brotchie	Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
000B36 (1992)	M. Stacy [États-Unis] ; Joseph Jankovic [États-Unis]	Tardive tremor.
000B37 (1992)	M R Luquin ; O. Scipioni ; J. Vaamonde ; O. Gershanik ; J A Obeso	Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
000C11 (2003)	Mark S. Baron ; W Brian Dalton	Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
000E17 (2004)	Susan Fox [Royaume-Uni] ; Montague Silverdale ; Mark Kellett ; Rhys Davies ; Malcolm Steiger ; Nicholas Fletcher ; Alan Crossman ; Jonathan Brotchie	Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Dyskinesia, Drug-Induced (drug therapy)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Dyskinesia, Drug-Induced (drug therapy)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dyskinesia, Drug-Induced (drug therapy)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024